期刊文献+

雄激素剥夺治疗后代谢并发症及其干预管理 被引量:3

Metabolic complications of androgen deprivation therapy and its intervention management
下载PDF
导出
摘要 雄激素剥夺治疗(ADT)是晚期前列腺癌的主要治疗方法。虽然ADT可显著延长患者的总生存期,但有时亦会对机体代谢造成严重影响。本文总结了ADT对身体构成、血脂及血糖水平、心血管系统等方面的不良影响,并对ADT代谢并发症干预管理的重要性进行论述。 Androgen deprivation therapy (ADT) is one of the dominant treatment options for advanced prostate cancer, which has been certified to significantly improve the overall survival of prostate cancer patients. However, it sometimes can also produce se- vere adverse effects on body metabolism. This review summarizes the adverse effects of ADT on body composition, the levels of choles- terol and blood glucose, and the cardiovascular system, and the intervention management of these metabolic complications as well.
作者 胡永慧 吴松 张蒙 HU Yong-hui1 , WU Song2, ZHANG Meng3(1. Department of Endocrinology, The Second Hospital of Tianfin Medical University, Tianfin 300211, China; 2. Department of Urology, Shenzhen Luohu People's Hospital, Shenzhen Following Precision Medical Research Insti- tute, Shenzhen, Guangdong 518001 , China ; 3. Department of Urology, The First Affiliated Hospital of Anhui Medi- cal University, Hefei, Anhui 230031, Chin)
出处 《中华男科学杂志》 CAS CSCD 北大核心 2018年第3期277-281,共5页 National Journal of Andrology
基金 广东省自然科学基金(2017A030313800)~~
关键词 前列腺癌 雄激素剥夺治疗 代谢并发症 干预管理 prostate cancer androgen deprivation therapy metabolic complication intervention management
  • 相关文献

参考文献1

二级参考文献21

  • 1DRAISMA G, ETZIONI R, TSODIKOV A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: impor- tance of methods and context[J]. J Natl Cancer Inst, 2009, 101 (6) : 374-383.
  • 2DRAISMA G, BOER R, OTTO SJ, et al. Lead times and over- detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer[J]. J Natl Cancer Inst, 2003, 95(12):868-878.
  • 3DONG F, KATTAN MW, STEYERBERG EW, et al. Valida- tion of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice[J]. J Urol, 2008, 180(1) :150-154.
  • 4RICHIE JP, CATALONA WJ, AHMANN FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination[J]. Urol- ogy, 1993, 42(4) :365-374.
  • 5JIANG X, ZHU S, FENG G, et al. Is an initial saturation pros- tate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis[J]. Eur Urol, 2013, 63(6):1031-1039.
  • 6ABUZALLOUF S, DAYES I, LUKKA H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature [J]. J Urol, 2004, 171 (6 Pt 1):2122-2127.
  • 7ZACHO HD, BARSI T, MORTENSEN JC, et al. Prospective multieenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer[J]. Clin Nucl Med, 2014, 39(1) :26-31.
  • 8STEPHENSON AJ, KATTAN MW, EASTHAM JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era[J]. J Clin Oncol, 2009, 27(26):4300-4305.
  • 9YOSSEPOWITCH O, EGGENER SE, SERIO AM, et al. Sec- ondary therapy, metastatic progression, and cancer- specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy[J]. Eur Urol, 2008,53 (5) : 950-959.
  • 10WALZ J, JONIAU S, CHUN FK, et al. Pathological results and rates of treatment failure in high risk prostate cancer pa- tients after radical prostatectomy[J]. BJU Int, 2011, 107: 765- 770.

共引文献23

同被引文献37

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部